Replies to post #210365 on Cytodyn Inc (CYDY)

[kgromax]

Wrong, this new endpoint was NOT defined before the study began:

https://www.clinicaltrials.gov/ct2/show/NCT04521114

Look for it. It is nowhere there.

For a good reason: after having seen the data (post-hoc analysis), they data dredged it to death, until they found some favorable statistics to back their storyline. Here, the haplotype subset. If this subset had been bad and the patients without the haplotype had better results, they would have exhibited that opposite subset instead. Exactly like the COVID trials (failed too) where, depending in which direction the wind was blowing, opposite rationales were pumped by stock promoters (« great for mild cases only » - « great for critical cases only » - « great for critical only but not too critical »). They have splitted by dosage for example this analysis. A subset of a subset. How strange. They could alternatively have splitted by age, presence of specific markers, etc…Hundreds of potential combinations they could choose from. Too easy.

Data dredging is the statistical equivalent of moving the goalposts. Of course when you move them you always end up scoring a goal.